|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-7-7
|
|
pubmed:abstractText |
The efficacy and safety of recombinant human erythropoietin (rhEPO) were tested when given subcutaneously (s.c.) in an escalating dose of 2000-10,000 units (U) daily in 60 patients with cancer-related anaemia (CRA). A positive response, defined as an increase in haemoglobin more than 2 g/dl and independence of blood transfusions was observed in 23 of 48 evaluable patients (48%) within a median of 8 wk. In detail, rhEPO corrected anaemia in 11 of 14 patients (79%) with malignant lymphoma, in 8 of 15 patients (53%) with multiple myeloma and in 4 of 10 patients (40%) with a solid tumour. The median dose of rhEPO in successful cases was 5000 U daily. Four patients with agnogenic myeloid metaplasia and 5 with myelodysplastic disorder failed to respond to rhEPO. No patient had any severe side effects. Pretreatment serum erythropoietin levels appeared to be a weak predictor for response to rhEPO treatment. In conclusion, rhEPO seems to be safe and effective in correcting CRA in certain groups of patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0902-4441
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
251-6
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:9186536-Adolescent,
pubmed-meshheading:9186536-Adult,
pubmed-meshheading:9186536-Aged,
pubmed-meshheading:9186536-Anemia,
pubmed-meshheading:9186536-Blood Transfusion,
pubmed-meshheading:9186536-Erythropoietin,
pubmed-meshheading:9186536-Female,
pubmed-meshheading:9186536-Ferritins,
pubmed-meshheading:9186536-Hematocrit,
pubmed-meshheading:9186536-Hemoglobins,
pubmed-meshheading:9186536-Humans,
pubmed-meshheading:9186536-Injections, Subcutaneous,
pubmed-meshheading:9186536-Iron,
pubmed-meshheading:9186536-Lymphoma,
pubmed-meshheading:9186536-Male,
pubmed-meshheading:9186536-Middle Aged,
pubmed-meshheading:9186536-Multiple Myeloma,
pubmed-meshheading:9186536-Myelodysplastic Syndromes,
pubmed-meshheading:9186536-Neoplasms,
pubmed-meshheading:9186536-Primary Myelofibrosis,
pubmed-meshheading:9186536-Recombinant Proteins,
pubmed-meshheading:9186536-Reticulocyte Count,
pubmed-meshheading:9186536-Transferrin
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Recombinant human erythropoietin in the treatment of cancer-related anaemia.
|
|
pubmed:affiliation |
Department of Internal Medicine (Cancer Research), West German Cancer Center, University of Essen Medical School, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
